Lannett Company, Inc.  

(Public, NYSE:LCI)   Watch this stock  
Find more results for LCI
27.65
-0.40 (-1.43%)
Dec 15 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 27.35 - 28.14
52 week 14.90 - 30.35
Open 28.10
Vol / Avg. 1.00M/838,807.00
Mkt cap 1.03B
P/E 24.71
Div/yield     -
EPS 1.12
Shares 37.67M
Beta 2.84
Inst. own 99%
Jan 30, 2018
Q2 2018 Lannett Company Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Jan 18, 2018
Lannett Company Inc Annual Shareholders Meeting (Estimated) - 9:00AM EST - Add to calendar
Jan 17, 2018
Lannett Company Inc Annual Shareholders Meeting - 9:00AM EST - Add to calendar
Dec 14, 2017
Lannett Company Inc at BMO Capital Markets Prescriptions for Success Healthcare Conference
Dec 13, 2017
Lannett Company Inc at Guggenheim Boston Healthcare Conference
Nov 15, 2017
Lannett Company Inc at Jefferies Global Healthcare Conference
Nov 6, 2017
Q1 2018 Lannett Company Inc Earnings Call - Webcast
Nov 6, 2017
Q1 2018 Lannett Company Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2017
Net profit margin 8.56% -0.09%
Operating margin 26.25% 13.56%
EBITD margin - 38.45%
Return on average assets 3.30% -0.03%
Return on average equity 9.35% -0.10%
Employees 1,126 -
CDP Score - -

Address

9000 State Rd
PHILADELPHIA, PA 19136-1615
United States - Map
+1-215-3339000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

Officers and directors

Jeffrey Farber Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Arthur P. Bedrosian J.D. Chief Executive Officer, Director
Age: 71
Bio & Compensation  - Reuters
Martin P. Galvan CPA Chief Financial Officer, Vice President - Finance, Treasurer
Age: 65
Bio & Compensation  - Reuters
John Kozlowski Corporate Chief Operating Officer
Age: 45
Bio & Compensation  - Reuters
Kevin R. Smith Senior Vice President - Sales and Marketing
Age: 57
Bio & Compensation  - Reuters
Robert Ehlinger Vice President - Logistics, Chief Information Officer
Age: 60
Bio & Compensation  - Reuters
Samuel H. Israel Vice President, General Counsel, Chief Legal Officer
Age: 56
Bio & Compensation  - Reuters
John M. Abt Vice President - Quality
Age: 52
Bio & Compensation  - Reuters
David Drabik Lead Independent Director
Age: 49
Bio & Compensation  - Reuters
Patrick G. LePore Independent Director
Age: 62
Bio & Compensation  - Reuters